T-cell Immunotherapy for Solid Tumors and Hematological Diseases
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 413
Special Issue Editor
Interests: adoptive cancer immunotherapy; gene therapy; hematopoietic stem cell transplantation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
From the first human-to-human blood transfusion in 1825 to the first allogeneic bone marrow transplant by Dr. Donald Thomas in 1957, cell and gene therapy research has been introduced to the bedside. Such endowments include the regulatory approval of cell and gene therapies for the treatment of monogenic diseases (Strimvelis, Zynteglo, Voretigene), regenerative medicine (Holoclar), cancer (Tebentafusp-tebn), and chimeric artificial receptors for lymphoma, leukemia, and multiple myeloma (lisocabtagene maralaucel, brexcabtagene autoleucel, tisagenleceucel, axicabtagene ciloleucel, idecabtagene vicleucel).
Investigations are ongoing to expand applications to other disease types and strategies for optimizing the function and safety, particularly regarding CAR T cells for the treatment of solid cancers, and anti-tumor specific T cells.
This collection aims to highlight discoveries and ongoing research in several fields of medicine, with a focus on T-cell immunotherapy for solid and hematological cancers.
Dr. Antonio Di Stasi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- gene therapy
- oncology
- hematology
